rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
11
|
pubmed:dateCreated |
2001-11-13
|
pubmed:abstractText |
Previous trials of topical trans-retinoic acid treatment of cervical intraepithelial neoplasia (CIN) grades 2 and 3 led to a statistically significant regression of CIN 2, but not CIN 3. We tested N-(4-hydroxyphenyl)retinamide (4-HPR), a promising oral retinoid that has been shown to induce apoptosis through nonretinoic receptor acid-mediated pathways, for its toxicity and efficacy against CIN 2/3.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
1078-0432
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
7
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
3356-65
|
pubmed:dateRevised |
2005-11-17
|
pubmed:meshHeading |
pubmed-meshheading:11705848-Adult,
pubmed-meshheading:11705848-Antineoplastic Agents,
pubmed-meshheading:11705848-Cervical Intraepithelial Neoplasia,
pubmed-meshheading:11705848-Cheilitis,
pubmed-meshheading:11705848-Cross-Over Studies,
pubmed-meshheading:11705848-Exanthema,
pubmed-meshheading:11705848-Female,
pubmed-meshheading:11705848-Fenretinide,
pubmed-meshheading:11705848-Humans,
pubmed-meshheading:11705848-Medical Futility,
pubmed-meshheading:11705848-Patient Compliance,
pubmed-meshheading:11705848-Photosensitivity Disorders,
pubmed-meshheading:11705848-Time Factors,
pubmed-meshheading:11705848-Treatment Outcome,
pubmed-meshheading:11705848-Uterine Cervical Neoplasms
|
pubmed:year |
2001
|
pubmed:articleTitle |
A randomized clinical trial of 4-hydroxyphenylretinamide for high-grade squamous intraepithelial lesions of the cervix.
|
pubmed:affiliation |
Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. mfollen@mdanderson.org.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|